Literature DB >> 23900599

[Novel morphological and molecular aspects of lung cancer].

A Warth1, A Stenzinger, W Weichert.   

Abstract

In recent years the classification of pulmonary cancer has seen a paradigm shift with respect to both morphological as well as molecular aspects. On the morphological side this includes novel criteria for tumor classification from biopsy material based on morphological and immunohistochemical aspects as well as a novel classification based on morphological patterns for pulmonary adenocarcinomas. In addition, this new classification now includes adenocarcinoma in situ as well as minimally invasive adenocarcinoma as novel entities and a variety of novel adenocarcinoma subtypes. This reclassification was accompanied and complemented by tremendous developments in the field of lung cancer genomics which paved the way for now widely established predictive molecular markers, e.g. epidermal growth factor receptor (EGFR) mutations and EML4-ALK translocations and will certainly lead to a variety of novel predictive markers not only for pulmonary adenocarcinoma but also for other pulmonary neoplasms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23900599     DOI: 10.1007/s00292-013-1787-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  55 in total

1.  Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification.

Authors:  Arne Warth; Judith Cortis; Ludger Fink; Annette Fisseler-Eckhoff; Helene Geddert; Thomas Hager; Klaus Junker; Gian Kayser; Julia Kitz; Florian Länger; Alicia Morresi-Hauf; German Ott; Iver Petersen; Albrecht Stenzinger; Alex Soltermann; Saskia Ting; Verena Tischler; Ekkehard Vollmer; Philipp A Schnabel; Wilko Weichert
Journal:  Virchows Arch       Date:  2012-06-23       Impact factor: 4.064

2.  Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing.

Authors:  Volker Endris; Roland Penzel; Arne Warth; Alexander Muckenhuber; Peter Schirmacher; Albrecht Stenzinger; Wilko Weichert
Journal:  J Mol Diagn       Date:  2013-08-21       Impact factor: 5.568

3.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Authors:  Masahiro Fukuoka; Yi-Long Wu; Sumitra Thongprasert; Patrapim Sunpaweravong; Swan-Swan Leong; Virote Sriuranpong; Tsu-Yi Chao; Kazuhiko Nakagawa; Da-Tong Chu; Nagahiro Saijo; Emma L Duffield; Yuri Rukazenkov; Georgina Speake; Haiyi Jiang; Alison A Armour; Ka-Fai To; James Chih-Hsin Yang; Tony S K Mok
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

4.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Authors:  Arne Warth; Thomas Muley; Michael Meister; Albrecht Stenzinger; Michael Thomas; Peter Schirmacher; Philipp A Schnabel; Jan Budczies; Hans Hoffmann; Wilko Weichert
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK.

Authors:  Roland Penzel; Peter Schirmacher; Arne Warth
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

6.  Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach.

Authors:  Tina Zahel; Sabine Krysa; Esther Herpel; Albrecht Stenzinger; Benjamin Goeppert; Peter Schirmacher; Hans Hoffmann; Philipp A Schnabel; Arne Warth
Journal:  Virchows Arch       Date:  2012-03       Impact factor: 4.064

7.  Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies.

Authors:  Arne Warth; Roland Penzel; Regine Brandt; Christine Sers; Jürgen R Fischer; Michael Thomas; Felix J F Herth; Manfred Dietel; Peter Schirmacher; Hendrik Bläker
Journal:  Virchows Arch       Date:  2012-03-15       Impact factor: 4.064

8.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors:  Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

9.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

10.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

View more
  7 in total

Review 1.  [Lung cancer. Developments, concepts and preview of the new WHO classification].

Authors:  I Petersen; A Warth
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

Review 2.  [Molecular diagnostics of non-small cell lung cancer: New markers and technologies].

Authors:  A Warth; V Endris; M Kriegsmann; A Stenzinger; R Penzel; N Pfarr; W Weichert
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

Review 3.  [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].

Authors:  A Warth
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

Review 4.  A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Authors:  M Dietel; K Jöhrens; M V Laffert; M Hummel; H Bläker; B M Pfitzner; A Lehmann; C Denkert; S Darb-Esfahani; D Lenze; F L Heppner; A Koch; C Sers; F Klauschen; I Anagnostopoulos
Journal:  Cancer Gene Ther       Date:  2015-09-11       Impact factor: 5.987

Review 5.  Lung cancer: developments, concepts, and specific aspects of the new WHO classification.

Authors:  Iver Petersen; Arne Warth
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-22       Impact factor: 4.553

Review 6.  [Molecular pathology of lung cancer. State of the art 2014].

Authors:  A Warth; V Endris; R Penzel; W Weichert
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

7.  Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.

Authors:  Ilija Nenadić; Jeanine Staber; Susanne Dreier; Guus Simons; Verena Schildgen; Michael Brockmann; Oliver Schildgen
Journal:  Cancers (Basel)       Date:  2017-07-11       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.